Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Monoisotopic mass
250.052446274
InChI
InChI=1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)
InChI Key
InChIKey=SEEPANYCNGTZFQ-UHFFFAOYSA-N
IUPAC Name
4-amino-N-(pyrimidin-2-yl)benzene-1-sulfonamide
Traditional IUPAC Name
sulfadiazine
SMILES
NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=N1
Độ hòa tan
77 mg/L (at 25 °C)
pKa (strongest acidic)
6.99
pKa (Strongest Basic)
2.01
Refractivity
64.2 m3·mol-1
Dược Lực Học :
Sulfadiazine is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus.
Cơ Chế Tác Dụng :
One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections. [PubChem]
Sulfadiazine is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. This enzyme is needed for the proper processing of para-aminobenzoic acid (PABA) which is essential for folic acid synthesis. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.
Dược Động Học :
▧ Route of Elimination :
Sulfadiazine is excreted largely in the urine.
Độc Tính :
Oral LD50 in mouse is 1500 mg/kg.
Chỉ Định :
For the treatment of rheumatic fever and meningococcal meningitis
Tương Tác Thuốc :
-
Chlorpropamide
Sulfonamide/sulfonylurea: possible hypoglycemia
-
Cyclosporine
The sulfonamide decreases the effect of cyclosporine
-
Fosphenytoin
The sulfonamide increases the effect of hydantoin
-
Methenamine mandelate
Possible crystallization of urates with this combination
-
Methotrexate
The sulfamide increases the toxicity of methotrexate
-
Phenytoin
The sulfonamide increases the effect of hydantoin
-
Tamoxifen
Sulfadiazine may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Sulfadiazine is initiated, discontinued or dose changed.
-
Tolbutamide
Tolbutamide and Sulfadiazine are strong CYP2C9 inhibitors and substrates. Decreased metabolism and clearance of both agents may occur during concomitant therapy. Consider alternate therpy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose(s) changed.
-
Torasemide
Sulfadiazine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Sulfadiazine is initiated, discontinued or dose changed.
-
Trimethoprim
The strong CYP2C9 inhibitor, Sulfadiazine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Sulfadiazine is initiated, discontinued or dose changed.
-
Warfarin
Sulfadiazine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if sulfadiazine is initiated, discontinued or dose changed.
-
Zafirlukast
Sulfadiazine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if sulfadiazine is initiated, discontinued or dose changed.
Dữ Kiện Thương Mại
Giá thị trường
-
Giá bán buôn : USD >2.5
Đơn vị tính : tablet
-
Giá bán buôn : USD >13.99
Đơn vị tính : jar
-
Giá bán buôn : USD >19.99
Đơn vị tính : jar
-
Giá bán buôn : USD >21.99
Đơn vị tính : jar
-
Giá bán buôn : USD >36.48
Đơn vị tính : jar
-
Giá bán buôn : USD >0.13
Đơn vị tính : g
-
Giá bán buôn : USD >0.25
Đơn vị tính : tablet
-
Giá bán buôn : USD >0.38
Đơn vị tính : tablet
-
Giá bán buôn : USD >0.42
Đơn vị tính : tab
Tài Liệu Tham Khảo Thêm
National Drug Code Directory